transforming biotechnology manufacturing infographic · central utilities manufacturing future...

1
ADMIN/ QC LABS Carbon emissions decrease * : 4-6x Energy use decrease: 4-6x Solid waste generation decrease: 2-3x Water use decrease: 10-12x 120k sq ft Will sit on 5 acres 1/5 of the cost and can be built in 2 years WAREHOUSE CENTRAL UTILITIES MANUFACTURING Future Facilities Will Allow for Greater Productivity in a Smaller Footprint New facility allows expansion almost anywhere in the world to support local market needs Disposable plastic containers eliminate need for costly cleaning and sterilization Single-use bioreactors Maximum size of 2,000 liters each Higher cellular productivity and cell densities result in smaller bioreactors and smaller plants Reconfigurable Technology Allows for Greater Speed and Efficiency Standardized, modular , and flexible design makes it easier to reconfigure to produce different drugs or move from one plant to another Resulting continuous production allows for reduced turnaround time between batches Single level processing suite with open floor plan Connected, continuous operational steps, fewer material transfers On-the-floor real-time quality analysis and control allows product to be released faster Standardized processes throughout development Complex, varied processes at different stages of drug development Streamlined Processes Result in Increased Flexibility Smaller, More Efficient Facilities Create Favorable Environmental Impact In keeping with its history of manufacturing innovation and excellence, Amgen is leading the way in the development and use of manufacturing technologies that will set the standard for the future. Planned and built around single products Expensive Time-consuming to reconfigure X X X Segregated operating suites on multiple levels Discrete operational steps, multiple transfers of drug material from place to place Time-consuming quality analysis and control post-production X X X 750K sq ft Sits on 80 acres across 3 buildings Cost $1 billion to build over 4 years Cost and footprint make geographic expansion difficult Fixed stainless steel bioreactors Ranging in size from 40 - 20,000 liters Complex network of piping to clean and sterilize between batches Future Facilities Conventional Facilities Transforming Biotechnology Manufacturing: Adapng Technology to a Changing Environment C 6 1,2 3 4 5 *Carbon emissions are dependent on geographical location; in general, carbon emission reduction will mirror energy reduction. References: 1 Amgen Inc. “Amgen to Build State-of-the-Art Manufacturing Facility in Singapore.” News release; January 16, 2013. 2 Data on file, Amgen; 2014. 3 Whitford W, BioProcess International, 10(5)s Supplement May 2012. 4 Zheng R, BioProcess International, Supplement April 2010. 5 Data on file, Amgen; 2013. © 2014 Amgen Inc. All rights reserved. 81948-R1-V1

Upload: phungnhan

Post on 01-Nov-2018

214 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Transforming Biotechnology Manufacturing Infographic · CENTRAL UTILITIES MANUFACTURING Future Facilities Will Allow for Greater Productivity in a Smaller Footprint New facility allows

ADMIN/QC LABS

Carbon emissionsdecrease*:

4-6xEnergy usedecrease:

4-6xSolid waste

generation decrease:

2-3xWater usedecrease:

10-12x

120ksq ft

Will sit on5 acres

1/5 of the cost andcan be built in

2 years

WAREHOUSE

CENTRAL UTILITIES

MANUFACTURING

Future Facilities Will Allow for GreaterProductivity in a Smaller Footprint

New facility allows expansionalmost anywhere in the world to support local market needs

Disposable plastic containerseliminate need for costly cleaning and sterilization

Single-usebioreactors

Maximum size of 2,000 liters each

Higher cellular productivity and cell densities result in smaller bioreactors and smaller plants

Reconfigurable Technology Allows for Greater Speed and Efficiency

Standardized, modular, and flexible design makes it easier to reconfigure to produce different drugs or move from one plant to another

Resulting continuous production allows for reduced turnaround time between batches

Single level processing suite with open floor plan Connected, continuous operational steps, fewer material transfers

On-the-floor real-time quality analysis and control allows product to be released faster

Standardized processesthroughout development

Complex, varied processes at different stages of drug development

Streamlined Processes Resultin Increased Flexibility

Smaller, More Efficient Facilities Create Favorable Environmental Impact

In keeping with its history of manufacturing innovation and excellence, Amgen is leading the way in the development and use of manufacturing technologies that will set the standard for the future.

Planned and built aroundsingle products

Expensive

Time-consuming to reconfigure

X

X

X

Segregated operating suiteson multiple levels

Discrete operational steps,multiple transfers of drug materialfrom place to place

Time-consuming quality analysis and control post-production

X

X

X

750Ksq ft

Sits on 80 acres

across 3 buildings

Cost $1 billion

to build over 4 years

Cost and footprint makegeographic expansion difficult

Fixed stainlesssteel bioreactors

Ranging in size from40 - 20,000 liters

Complex network of pipingto clean and sterilize between batches

Future FacilitiesConventional Facilities

Transforming Biotechnology Manufacturing:Adapting Technology to a Changing Environment

C6

1,23

4

5

*Carbon emissions are dependent on geographical location; in general, carbon emission reduction will mirror energy reduction.

References: 1 Amgen Inc. “Amgen to Build State-of-the-Art Manufacturing Facility in Singapore.” News release; January 16, 2013. 2 Data on file, Amgen; 2014. 3 Whitford W, BioProcess International, 10(5)s Supplement May 2012. 4 Zheng R, BioProcess International, Supplement April 2010. 5 Data on file, Amgen; 2013.

© 2014 Amgen Inc. All rights reserved. 81948-R1-V1